GlassScriptPhysician profile
Andrew Gottehrer
NPI 1013913359
$16,190.07
in general payments reported to CMS, 2019-2025
37 companies · $2,172 in 2025
The $2,172 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,368 · 2020: $1,895 · 2021: $2,276 · 2022: $2,490 · 2023: $1,842 · 2024: $2,148 · 2025: $2,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,161.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,041.04 | 2019-2025 | Bevespi Aerosphere, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $2,956.11 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,363.06 | 2019-2025 | Ofev, Spiriva Respimat, Jascayd |
| Mylan Specialty L.P. | $1,536.72 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $933.84 | 2019-2024 | Prolastin-C Liquid |
| United Therapeutics Corporation | $746.06 | 2019-2025 | Tyvaso, Tyvaso, Remodulin |
| Actelion Pharmaceuticals US, INC. | $504.62 | 2019-2025 | Opsumit, Uptravi |
| Genentech USA, INC. | $452.52 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $383.54 | 2019-2021 | |
| Advanced Respiratory, INC | $270.61 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $263.43 | 2021-2025 | Glassia |
| Insmed, INC. | $254.30 | 2019-2025 | Arikayce, Brinsupri |
| Electromed, INC. | $253.39 | 2019-2025 | Smartvest |
| Teva Pharmaceuticals USA, INC. | $248.92 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $234.04 | 2020-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $226.51 | 2019-2025 | |
| Philips North America LLC | $212.04 | 2019-2025 | Incourage Airway Clearance Therapy, (Ak6) Vest Therapy, Vest Therapy Und |
| Viatris Specialty LLC | $182.41 | 2025 | Yupelri |
| Verona Pharma, INC. | $174.15 | 2025 | Ohtuvayre |
| Covis Pharma Gmbh | $157.07 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $152.79 | 2019-2025 | Dupixent |
| Circassia INC. | $133.94 | 2019-2020 | |
| Baxter Healthcare | $96.46 | 2022-2023 | Hillrom - Vest System Model 105 Home Care |
| Merck Sharp & Dohme LLC | $85.83 | 2019-2025 | Zerbaxa |
| Allergan, INC. | $64.02 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $45.70 | 2019 | |
| Gilead Sciences, INC. | $32.02 | 2024 | Veklury |
| Abbvie INC. | $30.01 | 2021-2022 | |
| Inspire Medical Systems, INC. | $22.79 | 2025 | Inspire |
| Mallinckrodt Enterprises LLC | $21.48 | 2019 | |
| Ethicon INC. | $20.53 | 2025 | Monarch Platform |
| Vifor Pharma, INC. | $20.10 | 2024 | Zemaira |
| Inogen, INC. | $17.34 | 2022 | |
| Hikma Pharmaceuticals USA | $14.24 | 2023 | Ryaltris |
| Bayer Healthcare Pharmaceuticals INC. | $14.04 | 2020 | |
| Shire North American Group INC | $12.87 | 2019 | |
| Hill-Rom Company, INC | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Gottehrer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.